These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15363989)

  • 21. Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test.
    Steckler T; Lavreysen H; Oliveira AM; Aerts N; Van Craenendonck H; Prickaerts J; Megens A; Lesage AS
    Psychopharmacology (Berl); 2005 Apr; 179(1):198-206. PubMed ID: 15821950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anxiolytic- but not antidepressant-like activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGlu₄ receptor.
    Sławińska A; Wierońska JM; Stachowicz K; Pałucha-Poniewiera A; Uberti MA; Bacolod MA; Doller D; Pilc A
    Neuropharmacology; 2013 Mar; 66():225-35. PubMed ID: 22634361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective activation of group I metabotropic glutamate receptors upregulates preprodynorphin, substance P, and preproenkephalin mRNA expression in rat dorsal striatum.
    Mao L; Wang JQ
    Synapse; 2001 Jan; 39(1):82-94. PubMed ID: 11071713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The anxiolytic-like effect of 5-HT1B receptor ligands in rats: a possible mechanism of action.
    Chojnacka-Wójcik E; Kłodzińska A; Tatarczyńska E
    J Pharm Pharmacol; 2005 Feb; 57(2):253-7. PubMed ID: 15720791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression.
    Hughes ZA; Neal SJ; Smith DL; Sukoff Rizzo SJ; Pulicicchio CM; Lotarski S; Lu S; Dwyer JM; Brennan J; Olsen M; Bender CN; Kouranova E; Andree TH; Harrison JE; Whiteside GT; Springer D; O'Neil SV; Leonard SK; Schechter LE; Dunlop J; Rosenzweig-Lipson S; Ring RH
    Neuropharmacology; 2013 Mar; 66():202-14. PubMed ID: 22551786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The anxiolytic-like effect of the selective 5-HT6 receptor antagonist SB-399885: the impact of benzodiazepine receptors.
    Wesołowska A
    Eur J Pharmacol; 2008 Feb; 580(3):355-60. PubMed ID: 18096153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats.
    Pietraszek M; Sukhanov I; Maciejak P; Szyndler J; Gravius A; Wisłowska A; Płaźnik A; Bespalov AY; Danysz W
    Eur J Pharmacol; 2005 May; 514(1):25-34. PubMed ID: 15878321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity.
    Porter RH; Jaeschke G; Spooren W; Ballard TM; Büttelmann B; Kolczewski S; Peters JU; Prinssen E; Wichmann J; Vieira E; Mühlemann A; Gatti S; Mutel V; Malherbe P
    J Pharmacol Exp Ther; 2005 Nov; 315(2):711-21. PubMed ID: 16040814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling.
    Klodzinska A; Tatarczyńska E; Chojnacka-Wójcik E; Nowak G; Cosford ND; Pilc A
    Neuropharmacology; 2004 Sep; 47(3):342-50. PubMed ID: 15275823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide].
    Satow A; Maehara S; Ise S; Hikichi H; Fukushima M; Suzuki G; Kimura T; Tanak T; Ito S; Kawamoto H; Ohta H
    J Pharmacol Exp Ther; 2008 Aug; 326(2):577-86. PubMed ID: 18487514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects.
    Heilig M; McLeod S; Brot M; Heinrichs SC; Menzaghi F; Koob GF; Britton KT
    Neuropsychopharmacology; 1993 Jun; 8(4):357-63. PubMed ID: 8099792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anxiolytic-like effects of preferential dopamine D3 receptor agonists in an animal model.
    Rogóz Z; Skuza G; Kłodzińska A
    Pol J Pharmacol; 2003; 55(3):449-54. PubMed ID: 14506325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripheral metabotropic glutamate receptor 5 mediates mechanical hypersensitivity in craniofacial muscle via protein kinase C dependent mechanisms.
    Lee JS; Ro JY
    Neuroscience; 2007 Apr; 146(1):375-83. PubMed ID: 17306466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protective role for type 4 metabotropic glutamate receptors against ischemic brain damage.
    Moyanova SG; Mastroiacovo F; Kortenska LV; Mitreva RG; Fardone E; Santolini I; Sobrado M; Battaglia G; Bruno V; Nicoletti F; Ngomba RT
    J Cereb Blood Flow Metab; 2011 Apr; 31(4):1107-18. PubMed ID: 21157475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anxiolytic-like effects of the selective metabotropic glutamate receptor 5 antagonist MPEP after its intra-amygdaloid microinjection in three different non-conditioned rat models of anxiety.
    Pérez de la Mora M; Lara-García D; Jacobsen KX; Vázquez-García M; Crespo-Ramírez M; Flores-Gracia C; Escamilla-Marvan E; Fuxe K
    Eur J Neurosci; 2006 May; 23(10):2749-59. PubMed ID: 16817878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. (-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection.
    Maj M; Bruno V; Dragic Z; Yamamoto R; Battaglia G; Inderbitzin W; Stoehr N; Stein T; Gasparini F; Vranesic I; Kuhn R; Nicoletti F; Flor PJ
    Neuropharmacology; 2003 Dec; 45(7):895-906. PubMed ID: 14573382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders.
    Kalinichev M; Le Poul E; Boléa C; Girard F; Campo B; Fonsi M; Royer-Urios I; Browne SE; Uslaner JM; Davis MJ; Raber J; Duvoisin R; Bate ST; Reynolds IJ; Poli S; Celanire S
    J Pharmacol Exp Ther; 2014 Sep; 350(3):495-505. PubMed ID: 24947466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of chlordiazepoxide, bretazenil, L838,417 and zolpidem in a validated mouse Vogel conflict test.
    Mathiasen L; Mirza NR
    Psychopharmacology (Berl); 2005 Nov; 182(4):475-84. PubMed ID: 16133136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Group 1 mGlu-family proteins promote neuroadaptation to ethanol and withdrawal-associated hippocampal damage.
    Reynolds AR; Williams LA; Saunders MA; Prendergast MA
    Drug Alcohol Depend; 2015 Nov; 156():213-220. PubMed ID: 26442908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological evaluation of the anxiolytic-like effects of EMD 386088, a partial 5-HT6 receptor agonist, in the rat elevated plus-maze and Vogel conflict tests.
    Jastrzębska-Więsek M; Siwek A; Partyka A; Kubacka M; Mogilski S; Wasik A; Kołaczkowski M; Wesołowska A
    Neuropharmacology; 2014 Oct; 85():253-62. PubMed ID: 24905144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.